Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Down 50.1% in December

Bioxytran, Inc. (OTCMKTS:BIXT) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 7,224 shares, a decline of 50.1% from the December 15th total of 14,465 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 386,938 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily trading volume, of 386,938 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are short sold.

Bioxytran Stock Performance

Shares of BIXT opened at $0.06 on Thursday. The stock has a 50-day moving average of $0.07 and a two-hundred day moving average of $0.08. Bioxytran has a one year low of $0.04 and a one year high of $0.23. The stock has a market cap of $6.49 million, a P/E ratio of -2.00 and a beta of 2.15.

About Bioxytran

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.